Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline to Use Inpharmatica s ADME Technology

NEW YORK, March 22 (GenomeWeb News) - Inpharmatica has made its ADME (absorption, distribution, metabolism, and excretion) technology available to GlaxoSmithKline, the company said today.

 

Under the agreement, Inpharmatica, based in London, will apply its ADME technology to a number of GSK's drug discovery programs in the UK and in Europe.

 

Inpharmatica's ADME technology is part of its PharmaCarta chemogenomics platform that links genomic and proteomics data with chemistry data. The company acquired ADME technology last June from ArQule.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.